I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| platelet | 11 studies | 79% ± 23% | |
| megakaryocyte | 6 studies | 73% ± 27% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| platelet | 11 studies | 79% ± 23% | |
| megakaryocyte | 6 studies | 73% ± 27% |
Insufficient scRNA-seq data for expression of PF4 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 89% | 227.40 | 515 / 578 | 27% | 1.31 | 311 / 1155 |
| spleen | 100% | 650.33 | 241 / 241 | 0% | 0 | 0 / 0 |
| intestine | 11% | 6.79 | 105 / 966 | 76% | 9.87 | 402 / 527 |
| stomach | 18% | 11.00 | 64 / 359 | 69% | 6.27 | 197 / 286 |
| peripheral blood | 81% | 2156.97 | 755 / 929 | 0% | 0 | 0 / 0 |
| pancreas | 0% | 0.08 | 1 / 328 | 72% | 3.06 | 128 / 178 |
| esophagus | 1% | 0.52 | 13 / 1445 | 44% | 3.97 | 81 / 183 |
| liver | 35% | 17.67 | 79 / 226 | 7% | 0.51 | 28 / 406 |
| skin | 25% | 49.05 | 458 / 1809 | 12% | 0.37 | 56 / 472 |
| kidney | 9% | 5.02 | 8 / 89 | 26% | 0.73 | 238 / 901 |
| brain | 1% | 0.44 | 26 / 2642 | 27% | 0.75 | 190 / 705 |
| bladder | 0% | 0 | 0 / 21 | 25% | 2.42 | 125 / 504 |
| adrenal gland | 1% | 0.40 | 3 / 258 | 19% | 1.01 | 43 / 230 |
| thymus | 13% | 7.27 | 86 / 653 | 3% | 0.09 | 18 / 605 |
| uterus | 1% | 0.46 | 2 / 170 | 14% | 0.65 | 64 / 459 |
| adipose | 13% | 7.12 | 158 / 1204 | 0% | 0 | 0 / 0 |
| ovary | 0% | 0 | 0 / 180 | 13% | 1.20 | 55 / 430 |
| blood vessel | 12% | 6.82 | 160 / 1335 | 0% | 0 | 0 / 0 |
| breast | 8% | 3.44 | 35 / 459 | 1% | 0.04 | 16 / 1118 |
| heart | 8% | 5.20 | 69 / 861 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 3% | 0.04 | 1 / 29 |
| prostate | 0% | 0.11 | 1 / 245 | 1% | 0.02 | 7 / 502 |
| eye | 0% | 0 | 0 / 0 | 1% | 0.03 | 1 / 80 |
| muscle | 1% | 0.32 | 7 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0010744 | Biological process | positive regulation of macrophage derived foam cell differentiation |
| GO_0019221 | Biological process | cytokine-mediated signaling pathway |
| GO_0006954 | Biological process | inflammatory response |
| GO_0045651 | Biological process | positive regulation of macrophage differentiation |
| GO_0045347 | Biological process | negative regulation of MHC class II biosynthetic process |
| GO_0042832 | Biological process | defense response to protozoan |
| GO_0010628 | Biological process | positive regulation of gene expression |
| GO_0030593 | Biological process | neutrophil chemotaxis |
| GO_0030595 | Biological process | leukocyte chemotaxis |
| GO_0030168 | Biological process | platelet activation |
| GO_0016525 | Biological process | negative regulation of angiogenesis |
| GO_0070098 | Biological process | chemokine-mediated signaling pathway |
| GO_0007189 | Biological process | adenylate cyclase-activating G protein-coupled receptor signaling pathway |
| GO_0045653 | Biological process | negative regulation of megakaryocyte differentiation |
| GO_0071222 | Biological process | cellular response to lipopolysaccharide |
| GO_0061844 | Biological process | antimicrobial humoral immune response mediated by antimicrobial peptide |
| GO_2001240 | Biological process | negative regulation of extrinsic apoptotic signaling pathway in absence of ligand |
| GO_0002548 | Biological process | monocyte chemotaxis |
| GO_0051873 | Biological process | killing by host of symbiont cells |
| GO_0032760 | Biological process | positive regulation of tumor necrosis factor production |
| GO_0042127 | Biological process | regulation of cell population proliferation |
| GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005576 | Cellular component | extracellular region |
| GO_0062023 | Cellular component | collagen-containing extracellular matrix |
| GO_0031093 | Cellular component | platelet alpha granule lumen |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0008201 | Molecular function | heparin binding |
| GO_0048248 | Molecular function | CXCR3 chemokine receptor binding |
| GO_0008009 | Molecular function | chemokine activity |
| GO_0045236 | Molecular function | CXCR chemokine receptor binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | PF4 |
| Protein name | Platelet factor 4 Platelet factor 4 (PF-4) (C-X-C motif chemokine 4) (Iroplact) (Oncostatin-A) [Cleaved into: Platelet factor 4, short form (Endothelial cell growth inhibitor)] |
| Synonyms | CXCL4 SCYB4 |
| Description | FUNCTION: Released during platelet aggregation. Neutralizes the anticoagulant effect of heparin because it binds more strongly to heparin than to the chondroitin-4-sulfate chains of the carrier molecule. Chemotactic for neutrophils and monocytes. Inhibits endothelial cell proliferation, the short form is a more potent inhibitor than the longer form. . |
| Accessions | P02776 A0A8I5QJ57 ENST00000687529.1 ENST00000296029.4 |
